Company: Geron Corporation
Kaskela Law LLC is investigating claims on behalf of investors of Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN). The investigation concerns whether Geron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices, and whether Geron investors have been harmed as a result.
On September 27, 2018, Janssen Biotech, Inc. (“Janssen”) announced that it would end its “collaboration and license agreement with Geron Corporation for imetelstat. … Janssen will work with Geron to transition the imetelstat program back to the company.” Also on September 27, 2018, Geron disclosed that “the effective date of the termination is September 28, 2018, after which the licensed rights to the imetelstat program, including intellectual property rights generated under the collaboration, return to Geron without any continuing economic obligations to Janssen, and Janssen has no further obligations to fund any of the current ongoing imetelstat clinical trials.”
Following this news, shares of Geron’s stock declined $3.92 per share, or over 62% in value, to close on September 27, 2018 at $2.31 per share.
Geron investors who suffered financial harm as a result of the above are encouraged to contact Kaskela Law LLC at (888) 715 – 1740 to discuss their legal rights and options and/or complete the information form on this page.